APRI (Aprinoia Therapeutics) Loans Receivable: $0.00 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Loans Receivable?

Aprinoia Therapeutics APRI Loans Receivable is $0.00 Mil as of Dec. 2023.

Aprinoia Therapeutics's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Aprinoia Therapeutics Loans Receivable Related Terms

Aprinoia Therapeutics Loans Receivable Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Loans Receivable Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Loans Receivable
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable 0.00 0.00 0.00 0.00 0.00

Aprinoia Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Aprinoia Therapeutics (APRI) has a Loans Receivable of $0.00 Mil as of Dec. 2023. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Loans Receivable too high?
Aprinoia Therapeutics' current Loans Receivable is $0.00 Mil.
How does Aprinoia Therapeutics' Loans Receivable compare to ?
Aprinoia Therapeutics' Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Loans Receivable is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.